Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins.
- Author:
Wei HUANG
1
;
Hou-wen TIAN
;
Jiao REN
;
Jiang-tao FAN
;
Li ZHAO
;
Tao BIAN
;
Zhen-hua LU
;
Li RUAN
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Blotting, Western; Capsid Proteins; genetics; metabolism; Cells, Cultured; Chick Embryo; Cloning, Molecular; Female; Gene Expression; Genetic Vectors; genetics; Humans; Oncogene Proteins, Viral; genetics; metabolism; Papillomaviridae; genetics; immunology; Papillomavirus E7 Proteins; Papillomavirus Infections; immunology; prevention & control; virology; Papillomavirus Vaccines; genetics; immunology; therapeutic use; Recombinant Fusion Proteins; genetics; immunology; metabolism; Repressor Proteins; genetics; metabolism; Transfection; Tumor Virus Infections; immunology; prevention & control; virology; Uterine Cervical Neoplasms; immunology; prevention & control; virology; Vaccinia virus; genetics; Virus Replication
- From: Chinese Journal of Experimental and Clinical Virology 2005;19(3):240-243
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo generate a human papillomavirus (HPV16) prophylactic and therapeutic vaccine candidate for cervical cancer.
METHODSHPV16 major capsid protein L1 gene/minor capsid protein L2 gene and HPV16 early E6/E7 genes were inserted into a vaccinia virus expression vector. A strain of non-recombinant vaccinia virus containing the sequences was obtained through a homologous recombination and identified.
RESULTSDNA hybridization confirmed that the HPV16L1/L2/E6/E7 genes were integrated into vaccinia virus DNA. Western Blot result showed that full-length L1/L2/E6/E7 proteins were co-expressed in CEF cells infected with the recombinant virus.
CONCLUSIONNTVJE6E7CKL1L2 could be taken as a candidate of prophylactic and therapeutic vaccine for HPV-associated tumors and their precancerous transformations.